General MedicationsORALGeneric

LAMIVUDINE; ZIDOVUDINE

Standard Dose

30MG; 60MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview LAMIVUDINE; ZIDOVUDINE is listed in Drugs@FDA under application 202814 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE Form and strength TABLET, FOR SUSPENSION; ORAL - 30MG; 60MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2012-06-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; ZIDOVUDINE is listed in Drugs@FDA under application 202814 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE Form and strength TABLET, FOR SUSPENSION; ORAL - 30MG; 60MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2012-06-15 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.